Home › Funds › Context Capital Management, LLC › ZBIO

Context Capital Management, LLC position in ZBIO

ZENAS BIOPHARMA INC · Health Care

Context Capital Management, LLC reported holding 31,050,000 shares of ZBIO (ZENAS BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$39.7M, representing 1.32% of its reported portfolio and ranking #29 among its reported holdings. Context Capital Management, LLC has disclosed ZBIO holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

Latest position (Q3 2026)31.05M sh
Reported value held$39.70M
Portfolio Weight1.32%
First reportedQ1 2026
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Context Capital Management, LLC's ZBIO position evolved

Context Capital Management, LLC first disclosed a stake in ZBIO in Q1 2026 at 29,100,000 shares (US$30.1M). The position peaked in Q2 2026 at 35,800,000 shares, worth US$42.6M. Across 3 filings, Context Capital Management, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 31,050,000 shares valued at US$39.7M — a reduction of -4,750,000 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q1 2026 29.10M $30.12M New
Q2 2026 35.80M $42.60M Add
Q3 2026 31.05M $39.70M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ZBIO and 13F data

ZBIO (ZENAS BIOPHARMA INC) is a Health Care company. 62 other funds we track also report a position in ZBIO — the largest reported positions include SR ONE CAPITAL MANAGEMENT, LP (US$127.9M), NEA Management Company, LLC (US$102.1M), Enavate Sciences GP, LLC (US$99.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ZBIO

All ZBIO fund holders →

FAQ

How long has Context Capital Management, LLC held ZBIO?

Context Capital Management, LLC has disclosed ZBIO holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

What is Context Capital Management, LLC's current position in ZBIO?

As of Q3 2026, Context Capital Management, LLC holds 31.05M shares of ZBIO (ZENAS BIOPHARMA INC), valued at $39.70M, representing 1.32% of its reported portfolio and ranking #29.

Has Context Capital Management, LLC been buying or selling ZBIO?

In the latest 13F filing (Q3 2026), Context Capital Management, LLC reduced its position in ZBIO. The position peaked in Q2 2026 at 35.80M shares.

Which other funds hold ZBIO?

Other major institutional holders of ZBIO include SR ONE CAPITAL MANAGEMENT, LP, NEA Management Company, LLC, Enavate Sciences GP, LLC, among 62 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.